Billerica, Massachusetts, May 15, 2017 — MilliporeSigma today took a significant step toward increasing manufacturing flexibility and enabling higher productivity with the launch of the EX-CELL® Advanced™ HD Perfusion Medium. This first off-the-shelf, high-density cell culture media supports perfusion processes and facilitates high productivity at low perfusion rates, increasing production yield and speed to clinic.
Biomanufacturers are moving toward perfusion processes, the next generation in manufacturing, as they seek to cut costs while increasing quality and efficiency. Perfusion processes, however, require a new type of medium to facilitate high productivity at low perfusion rates. MilliporeSigma’s EX-CELL® Advanced™ HD Perfusion Medium meets “next-gen” manufacturing requirements, allowing customers to achieve a more optimal output than they would using conventional batch or fed-batch processes.
“This launch is a major milestone on the road to truly enabling next generation processing,” said Udit Batra, CEO, MilliporeSigma. “The benefits of perfusion technology include increased cost efficiency, decreased risk and enhanced manufacturing flexibility—ultimately advancing our customers’ production capabilities and increasing access to therapies for people worldwide.”
A benefit of perfusion processing is higher protein yields, compared with fed-batch, which has been the primary mammalian cell cultivation mode for biopharma manufacturing over the past few decades. Perfusion technology is compatible with small portable plants and can be used with many drug types over a range of production scales.
MilliporeSigma’s EX-CELL® Advanced™ HD Perfusion Medium is the most recent addition to the company’s EX-CELL® Advanced™ product line, which offers increased performance, streamlines regulatory compliance and provides the supply chain security needed in today’s evolving biopharmaceutical environment.
About the Life Science Business of Merck KGaA, Darmstadt, Germany
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has 21,000 employees and 60 manufacturing sites worldwide, with a portfolio of more than 300,000 products enabling scientific discovery. Udit Batra is the global chief executive officer of MilliporeSigma.
Merck KGaA, Darmstadt, Germany completed its $17 billion acquisition of Sigma-Aldrich in November 2015, creating a leader in the $125 billion global life science industry.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 52,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene-editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2018, Merck KGaA, Darmstadt, Germany, generated sales of €14.8 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company. For more information about Merck, KGaA, Darmstadt, Germany, visit www.emdgroup.com.